Heart Failure Drug Shows Promise

Monday, 02 Sep 2013 10:28 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
An experimental drug from Novartis to treat heart failure proved equally effective regardless of the age of patients or whether they had other medical problems, clinical trial results presented on Monday showed.

The drug, serelaxin, which is a form of a human hormone that relaxes blood vessels and eases stress on the heart and other organs, is viewed as an important medicine in the Swiss drugmaker's developmental pipeline.

Analysts at Jefferies expect the drug to generate peak sales of $1.5 billion a year.

Results from a Phase III study last November found it reduced deaths by 37 percent compared with placebo - and the latest data offers further insight by showing how it performed in different patient sub-groups.

The drug led to reduced dyspnea, or breathlessness, and fewer deaths after six months in all patient groups, including those with impaired kidney function, those aged 75 or older, and those with atrial fibrillation, or irregular heartbeats.

The new findings were presented at the European Society of Cardiology congress in Amsterdam, where heart doctors have highlighted the enormous need for new treatments for acute heart failure, in which the heart is unable to pump enough blood.

Some 2 million patients are hospitalized each year in Europe and United States as a result of heart failure, and about half of all patients die within five years of being diagnosed with the condition.

Medical treatment of heart failure has changed little since the 1970s but Novartis hopes serelaxin will soon offer cardiologists a new therapy option.

U.S. regulators in June gave serelaxin "breakthrough therapy" status, potentially fast-tracking its development and approval.

The Novartis drug is currently being assessed by health authorities around the world, including the U.S. Food and Drug Administration and the European Medicines Agency.

Novartis previously disclosed that while serelaxin met one of the study's two primary goals by reducing deaths and relieving dyspnea, it failed to hit a secondary combined objective of lowering cardiovascular death and reducing the need for patients to go back into hospitals.

Researchers view the life-saving benefit as the more important measure, although many still want to see further evidence of the drug's performance given past disappointments in the field.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

Best, Worst Snack Bars for Health

Thursday, 31 Jul 2014 09:53 AM

Snack bars are convenient, portable, and often better for you than chips or cookies. But not all snack bars are created  . . .

Depression Is Risk Factor for Dementia: Researchers

Thursday, 31 Jul 2014 09:22 AM

Older people with depression are more likely to develop dementia, but researchers have been unable to explain the exact  . . .

Ebola Spread Prompts State of Emergency in Sierra Leone

Thursday, 31 Jul 2014 08:40 AM

The president of Sierra Leone declared a public health emergency as the Ebola crisis blamed for nearly 700 deaths deepen . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved